Stefan Antosik - Production Director
Mr Antosik has 28 years management experience in the pharmaceutical industry. Previous positions include Deputy Managing Director of Syntex Ireland and Managing Director of Angus Fine Chemicals. In these roles he was responsible for all site functions including manufacturing, engineering, quality and project management.

Prior to joining GW, Mr Antosik was Production Director with Scotia Pharmaceuticals Ltd and was responsible for the successful regulatory manufacturing submission in both the USA and Europe for Scotia's most important oncology drug. Also at Scotia, he managed the drug substance technology transfer, plant build, commissioning and process scale-up. The plant passed a pre-approval inspection by the FDA last year.

Rajiv Dave - Director of Special Technologies
Mr Dave has fifteen years experience in the electronics industry covering a wide range of technologies including seven years of experience in design and development for the BBC where he worked on systems such as NICAM stereo sound, digital audio-based routers and digital audio monitoring equipment.

Prior to joining GW Pharmaceuticals, Mr Dave was Technical Director for an electronics company where he led the design and development team and managed new product introductions in the UK.

Mr Dave is also a director of a UK-based design consultancy that has a broad level of expertise in electronic and software design and development ranging from GPS-based navigation systems, consumer products, audio video systems, broadcast systems, communication technologies through to medical devices.

Marilyn Emery - Director of Quality
Mrs Emery has over 20 years management experience in the pharmaceutical and related industries, including both large multinational organisations and small entrepreneurial companies. Before working with GW, Mrs Emery was Group Quality Assurance Manager with Scotia Holdings PLC, where she was responsible for the creation and management of quality systems, that were involved in inspections and approval by both US and UK Regulatory Authorities. Prior to that she was Technical Affairs Manager for Sterling-Winthrop, now Sanofi-Synthelabo, where she was responsible for a variety of technical projects, including preparation of drug master files and Regulatory support.

Mrs Emery has particular experience with other natural products developed for use as pharmaceuticals, in particular Evening Primrose Oil, acting as the Expert in European regulatory dossiers. She has also been involved in technical transfer of product from R & D through to commercial manufacturing and distribution.

Mrs Emery is a Qualified Person, a Fellow of the Royal Society of Chemistry and a member of British Institute of Regulatory Affairs.

Dr Peter Gibson - Technical Director
Dr Gibson has 18 years experience in pharmaceutical development, working with new chemical entities and generic products, in both contract research and established pharmaceutical companies.

Prior to joining GW Pharmaceuticals Dr Gibson was Director of Scientific Services for Elan Transdermal Technologies (UK) Limited (previously Ethical Pharmaceuticals Ltd) and was responsible for a wide range of technical and scientific activities for the company, including formulation development, analytical services, bioanalysis and information technology services.

Dr Gibson was co-founder of Bioanalytical Research Ltd in 1985, a contract research company specialising in bioanalysis for the pharmaceutical industry, which was sold in 1990 to Ethical Pharmaceuticals Ltd

Professor Roger Pertwee - Director of Pharmacology
Professor Pertwee joined GW as Director of Pharmacology in March 2002 but retains his position as Professor of Neuropharmacology at the University of Aberdeen. He is one of the world's leading cannabinoid scientists, having researched this area for over 30 years, and is the author of over 240 publications. He is frequently consulted on the therapeutic potential of cannabis and cannabinoids by parliamentary committees and leading medical organisations and has been involved with both the 1998/99 Royal Pharmaceutical Society working party on cannabis and the House of Lords Science & Technology Committee investigation into cannabis.

Professor Pertwee is also Co-chair of the International Union of Pharmacology (IUPHAR) Subcommittee on Cannabinoid Receptors and has also previously held the positions of President and International Secretary for the International Cannabinoid Research Society (ICRS).

David Potter - Director of Botanical Research and Cultivation
Mr Potter has twenty-three years research and development experience as a horticulturalist and agronomist. After brief contracts with the Ministry of Agriculture, he joined a multinational petrochemicals company in 1976 testing novel pesticides and plant growth regulants in glasshouse and field grown crops. Mr Potter was a Senior Assistant Scientist before becoming Head of Security and Estate Services in 1993.

Prior to joining GW in 1998 as its first employee, Mr Potter worked as an independent consultant in the registration of novel pesticides. Mr Potter is a Chartered Biologist, a Member of the Institute of Biology and a Member of the Institute of Occupational Safety and Health.

Dr Philip Robson - Director of the Cannabinoid Research Institute
Dr Robson is an expert in the therapeutic potential of cannabis and cannabinoids. In 1996 he was commissioned by the Department of Health to carry out a critical review of the relevant scientific literature and in 1998 was called on to submit both written and verbal evidence to the House of Lords Science & Technology Committee investigation into cannabis.

Prior to joining the Group, Dr Robson was for the previous ten years, a Consultant Psychiatrist in Oxford and Senior Clinical Lecturer in the Oxford University Department of Psychiatry. In addition to his duties as Medical Director of the Company, Dr Robson retains the position of Senior Research Fellow in the Oxford University Department of Psychiatry.

Prior to taking up his psychiatry posts at Oxford, Dr Robson worked for eight years within the pharmaceutical industry, initially as a clinical pharmacologist and then as Director of Clinical Research at Wyeth Laboratories.

Colin Stott - Director of Research & Development Operations
Mr Stott has fourteen years experience in the pharmaceutical industry covering a wide range of new chemical entities, biotechnology products and plant-based medicines, with 11 years experience of clinical development and project management.

Prior to joining GW, Mr Stott was Clinical Programme Manager & International Project Leader at Napp Pharmaceuticals Ltd, leading an international joint development programme of a plant-based medicine. Prior to this he was Clinical Projects Manager at the plant medicines company Phytopharm plc between 1996 and 1999, managing clinical and pre-clinical development programmes. Mr Stott also has experience gained at Astra Zeneca, Schering-Plough Limited, Genzyme (UK) Limited and Alpha Therapeutics Limited (now Grupo Grifols).

Alison Thompson – Director of Regulatory Affairs
Mrs Thompson has been with GW since 1999 and has worked in the field of management of regulatory affairs for over 14 years. Before joining GW she worked at Novartis as Manager, Regulatory Affairs, in the veterinary products division. Prior to entering the life sciences industry, Mrs Thompson worked for 10 years as an agricultural scientist.

Alice Mead - Director of US Professional Relations
Ms Mead is an attorney specialising in health care law. For eleven years prior to joining GW, she served as Legal Counsel to the California Medical Association, the largest state medical association in the United States. During that time, she has developed special expertise in the legal and regulatory issues surrounding the production of medicinal cannabis. She has also prepared detailed guidelines on the subject for the medical profession, which have been widely adopted throughout that State and the US generally.

Prior to joining the California Medical Association, Ms Mead served as a litigator for Morrison & Foerster and was previously a law professor at Arizona State University College of Law.

Richard Potts - Clinical Operations Director
Mr Potts has been with GW Pharmaceuticals since 2001 and has worked in the pharmaceutical industry for over 13 years. Prior to joining GW Pharmaceuticals, Mr Potts worked for Astra Zeneca in Sweden and then for Napp Pharmaceuticals in the UK as a Clinical Research Scientist where his principal responsibilities and achievements included the conception, design and execution of Phase II, III and IV Pan European clinical studies, investigating schedule II controlled drug substances.

Over the past 5 years, Mr Potts has successfully expanded GW Pharmaceuticals’ clinical operations into Mainland Europe, Eastern Europe, Canada and the USA. He has disease area experience in Pain, (neuropathic, inflammatory and nociceptive), Multiple Sclerosis, Asthma and Hypertension.

Dean Putt - Supply Chain Manager
Dean has over 15 years operations management experience in the FMCG and pharmaceutical industries.  His career started in manufacturing with Kraft Jacob Suchard before moving to Cadbury Schweppes where he made the transition from Production Management to Supply Chain Management and became responsible for the planning function. 

More recently he was Materials Manager for Abbott Laboratories UK where his responsibilities covered New Product Introduction, Demand Management, Planning, Purchasing and Distribution/Warehousing.